Valuation: Myriad Genetics, Inc.

Market Cap 60Cr 52Cr 48Cr 44Cr 84Cr 5.74TCr 85Cr 574.54Cr 225.7Cr 2.8TCr 223.81Cr 218.89Cr 9.68TCr P/E 2026 *
-8.3x
P/E 2027 * -11.9x
Enterprise Value 60Cr 52Cr 48Cr 44Cr 84Cr 5.74TCr 85Cr 574.54Cr 225.7Cr 2.8TCr 223.81Cr 218.89Cr 9.68TCr EV / Sales 2026 *
0.69x
EV / Sales 2027 * 0.65x
Free-Float
96.24%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week+1.48%
Current month+8.41%
1 month+45.65%
3 months+23.80%
6 months+4.56%
Current year+0.65%
1 week 5.67
Extreme 5.67
6.43
1 month 4.22
Extreme 4.22
6.43
Current year 3.53
Extreme 3.53
7.15
1 year 3.53
Extreme 3.53
8.59
3 years 3.53
Extreme 3.53
29.3
5 years 3.53
Extreme 3.53
36.95
10 years 3.53
Extreme 3.53
50.44
Manager TitleAgeSince
Chief Executive Officer 54 30/04/2025
Director of Finance/CFO 43 16/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman 67 23/03/2020
Director/Board Member 71 10/06/2010
Director/Board Member 66 25/09/2019
Date Insider Type Main position Quantity % Market Cap.
23/06/26 Other

Director

0 0%
11/06/26 Free

Executive/Senior Manager

5,000 0.0053%
11/06/26 Free

Chief Executive Officer

3,542 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%+1.48%+22.33%-72.65% 60Cr
-4.88%-5.53%+224.20%+309.29% 2.16TCr
+1.18%+5.13%-38.55%-22.61% 969.35Cr
+0.75%-0.83%+41.25%+20.26% 679.19Cr
-2.78%+3.20%+259.58%-24.61% 580.82Cr
+2.44%+9.01%-16.48%-28.79% 509.8Cr
-5.61%-7.78%-47.52% - 493.56Cr
+0.46%+4.81%-22.64%-25.61% 421.07Cr
+7.48%+20.79%+83.44%+108.39% 414.98Cr
+2.00%+7.26%-11.87%-39.00% 273.96Cr
Average -0.09%+7.40%+49.37%+24.96% 656.32Cr
Weighted average by Cap. -1.26%+6.12%+94.04%+107.16%

Financials

2026 *2027 *
Net sales 86Cr 75Cr 70Cr 64Cr 121.24Cr 8.32TCr 123.34Cr 832.51Cr 327.04Cr 4.06TCr 324.3Cr 317.18Cr 14TCr 92Cr 80Cr 74Cr 68Cr 128.57Cr 8.82TCr 130.81Cr 882.9Cr 346.83Cr 4.31TCr 343.93Cr 336.37Cr 15TCr
Net income -7.15Cr -6.25Cr -5.78Cr -5.3Cr -10Cr -688.78Cr -10Cr -69Cr -27Cr -336.35Cr -27Cr -26Cr -1.16TCr -5.1Cr -4.46Cr -4.12Cr -3.78Cr -7.16Cr -491.22Cr -7.28Cr -49Cr -19Cr -239.88Cr -19Cr -19Cr -828.16Cr
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
17/26/17 $6.190 -1.90% 9,65,864
15/26/15 $6.310 +4.47% 11,00,550
14/26/14 $6.040 +3.07% 8,96,466
13/26/13 $5.860 +0.51% 8,11,599
10/26/10 $5.830 -4.43% 8,56,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
6.310USD
Average target price
6.250USD
Spread / Average Target
-0.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock